La cadena de opciones muestra datos clave de las opciones de acciones de Cidara Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cidara Therapeutics..

Cidara Therapeutics (NASDAQ:CDTX) Bolsa, Cadena de Opciones

CIDARA THERAPEUTICS INC

Cidara Therapeutics

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Inc

Cantor Fitzgerald analyst Eric Schmidt reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from Overweight to Overweight.

News

Reiteration

Analyst Ratings

CDTX

Cantor Fitzgerald Reiterates Overweight on Cidara Therapeuticsto Overweight

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $35 to $36.

Price Target

Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $36

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $47 price target.

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

RBC Capital analyst Gregory Renza maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Outperform and raises the price target from $31 to $35.

RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $35

Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and maintains $35 price target.

Needham Reiterates Buy on Cidara Therapeutics, Maintains $35 Price Target

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $35 to $50.

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $50

Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $33 to $35.

Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and raises the price target from $46 to $47.

JMP Securities Maintains Market Outperform on Cidara Therapeutics, Raises Price Target to $47

Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of $(2.71) by 38.75 percent. This is a 27.19 percent increase over losses of $(2.28) per share from the same period last year.

Earnings

Earnings Beats

Cidara Therapeutics Q1 EPS $(1.66) Beats $(2.71) Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $46 price target.

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT.

Biotech

General

Cidara Therapeutics Announces Participation In WHO Panel On H5N1 Influenza Preparedness And Response, Discussing Pharmaceuticals As Preventive Tools On March 19, 2025

Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>), a biotechnology company using its proprietary Cloudbreak&#xAE;&nbsp;platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study.
Presentation details:
Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Study to Evaluate the Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for Prevention of Influenza in Subjects not at Risk for Influenza Complications

Cidara Therapeutics Announces 2 Presentations On CD388 In Influenza At ICAR 2025

Key Findings
<ul>
<li>The publication describes CD388 and its potential for universal activity across influenza A and B viruses in cellular and animal models.
<ul>
<li>Administration of CD388 resulted in the following:
<ul>
<li>Potent, universal activity against all influenza A and B virus strains, including high pathogenicity strains like H5N1, also known as avian influenza or bird flu, and strains that are resistant to approved neuraminidase inhibitors</li>
<li>Low potential for resistance development</li>
<li>Efficacy at similar exposures in immune-competent and immune-compromised lethal challenge models in mice demonstrating that efficacy is driven predominantly by the intrinsic antiviral activity of CD388</li>
</ul>
</li>
</ul>
</li>
</ul>
CD388 is currently under clinical evaluation in the ~5000 patient Phase 2b NAVIGATE trial, evaluating CD388 for the single-dose prevention of seasonal influenza in healthy unvaccinated adult subjects.

Health Care

Cidara Therapeutics Announced The Publication Of Preclinical Data Assessing CD388, The Company's Influenza Drug-fc Conjugate, In The Peer-reviewed Scientific Journal Nature Microbiology

Citizens Capital Markets analyst Roy Buchanan initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform rating and announces Price Target of $46.

Initiation

Citizens Capital Markets Initiates Coverage On Cidara Therapeutics with Market Outperform Rating, Announces Price Target of $46

HC Wainwright &amp; Co. analyst Ed Arce maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy and raises the price target from $24 to $35.

HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Raises Price Target to $35

Press Releases

Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Management

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

Comments

Cidara Therapeutics

Cidara Therapeutics (CDTX) Opciones

Cidara Therapeutics (NASDAQ:CDTX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL